EU's heath regulator reviewing Pfizer-BioNTech COVID-19 vaccine in real-time

Following assessment process for AstraZeneca’s COVID-19 vaccine candidate, European health regulator is currently reviewing potential vaccine being developed by Pfizer and BioNTech in real-time. As per reports, European Medicines ncy (EMA) said on October 6 that its human medicines committee was evaluating first batch of data on COVID-19 vaccine and would keep doing so until eugh data is collected to conclude with a final decision. 

Pfizer and BioNTech have said in a joint statement that start of review is based on data derived from labs (n-clinical), animal and human testing. It ded furr that y would continue to submit data as it emerged. Moreover, in a bid to finish review process swiftly, EMA is reportedly using “rolling reviews”, that is, by studying data as it is submitted inste of waiting for all data to be me available. 

Just last week, EMA h started reviewing COVID-19 vaccine candidate developed by AstraZeneca and Oxford University, AZD1222 or ChOx1 nCoV-19. This has also increased chances of British vaccine to become first one that is approved in region for COVID-19 while global infections have continued to soar. Pfizer and BioNTech’s vaccine is called BNT162b2. And while AZD1222 uses a diluted version of a chimpanzee common cold virus against vel coronavirus, BNT162b2 uses ribonucleic acid which acts as a chemical messenger.

Re - White House Nixes Updated FDA Guidelines On Vaccine Approval

Re - COVID Vaccine Trials For Kids Should Begin, Says Oxford Study Citing Role In Transmission

 Trials for kids should begin, says Oxford study

Meanwhile, a recent study published by Oxford has said that coronavirus vaccine trials for children should ‘begin w’, given ir susceptibility to virus. While COVID-19 vaccine trials for ults have moved to Phase III, y are yet to start for children. researchers have said that direct coronavirus impact upon children is ‘greater’ than what has alrey been observed. y also believe that role of children in transmission of coronavirus is under-appreciated. 

authors of study speculated that delaying Phase II vaccine clinical trials in children will delay recovery from COVID-19 and unnecessarily prolong its impact upon children’s education, health and emotional well-being. Given potential direct and indirect benefits of paediatric vaccination, authors said that implementation of Phase II clinical trials for Covid-19 vaccines should ‘begin w’. 

Re - White House Nixes Tougher FDA Guidelines On Vaccine Approval

Re - COVID-19 Vaccine: Chinese Company Seeks Co-financing For Phase-3 Trial In Banglesh